Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia von Stone, R M, Fischer, T, Paquette, R, Schiller, G, Schiffer, C A, Ehninger, G, Cortes, J, Kantarjian, H M, DeAngelo, D J, Huntsman-Labed, A, Dutreix, C, del Corral, A, Giles, F

Volltext

The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy von Wang, L D, Rao, T N, Rowe, R G, Nguyen, P T, Sullivan, J L, Pearson, D S, Doulatov, S, Wu, L, Lindsley, R C, Zhu, H, DeAngelo, D J, Daley, G Q, Wagers, A J

Volltext

Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia von DeAngelo, D J, Stevenson, K E, Dahlberg, S E, Silverman, L B, Couban, S, Supko, J G, Amrein, P C, Ballen, K K, Seftel, M D, Turner, A R, Leber, B, Howson-Jan, K, Kelly, K, Cohen, S, Matthews, J H, Savoie, L, Wadleigh, M, Sirulnik, L A, Galinsky, I, Neuberg, D S, Sallan, S E, Stone, R M

Volltext

Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial von DeAngelo, D J, George, T I, Linder, A, Langford, C, Perkins, C, Ma, J, Westervelt, P, Merker, J D, Berube, C, Coutre, S, Liedtke, M, Medeiros, B, Sternberg, D, Dutreix, C, Ruffie, P-A, Corless, C, Graubert, T J, Gotlib, J

Volltext

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia von Feldman, E J, Cortes, J, DeAngelo, D J, Holyoake, T, Simonsson, B, O'Brien, S G, Reiffers, J, Turner, A R, Roboz, G J, Lipton, J H, Maloisel, F, Colombat, P, Martinelli, G, Nielsen, J L, Petersdorf, S, Guilhot, F, Barker, J, Kirschmeier, P, Frank, E, Statkevich, P, Zhu, Y, Loechner, S, List, A

Volltext

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts von Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M, Ottmann, O G

Volltext

Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503) von Blum, W, Sanford, B L, Klisovic, R, DeAngelo, D J, Uy, G, Powell, B L, Stock, W, Baer, M R, Kolitz, J E, Wang, E S, Hoke, E, Mrózek, K, Kohlschmidt, J, Bloomfield, C D, Geyer, S, Marcucci, G, Stone, R M, Larson, R A

Volltext

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies von DeAngelo, D J, Spencer, A, Bhalla, K N, Prince, H M, Fischer, T, Kindler, T, Giles, F J, Scott, J W, Parker, K, Liu, A, Woo, M, Atadja, P, Mishra, K K, Ottmann, O G

Volltext

KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32) von Levine, R L, Wadleigh, M, Sternberg, D W, Wlodarska, I, Galinsky, I, Stone, R M, DeAngelo, D J, Gary Gilliland, D, Cools, J

Volltext

HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia von Akahane, K, Sanda, T, Mansour, M R, Radimerski, T, DeAngelo, D J, Weinstock, D M, Look, A T

Volltext

SYK regulates mTOR signaling in AML von Carnevale, J, Ross, L, Puissant, A, Banerji, V, Stone, R M, DeAngelo, D J, Ross, K N, Stegmaier, K

Volltext

Ponatinib-induced pityriasiform, folliculocentric and ichthyosiform cutaneous toxicities von Alloo, A., Sheu, J., Butrynski, J.E., DeAngelo, D.J., George, S., Murphy, G.F., LeBoeuf, N.R.

Volltext

A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma von Papayannidis, C, DeAngelo, D J, Stock, W, Huang, B, Shaik, M N, Cesari, R, Zheng, X, Reynolds, J M, English, P A, Ozeck, M, Aster, J C, Kuo, F, Huang, D, Lira, P D, McLachlan, K R, Kern, K A, Garcia-Manero, G, Martinelli, G

Volltext

Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy von DeAngelo, D J

Volltext

A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome von Cools, Jan, DeAngelo, Daniel J, Gotlib, Jason, Stover, Elizabeth H, Legare, Robert D, Cortes, Jorges, Kutok, Jeffrey, Clark, Jennifer, Galinsky, Ilene, Griffin, James D, Cross, Nicholas C.P, Tefferi, Ayalew, Malone, James, Alam, Rafeul, Schrier, Stanley L, Schmid, Janet, Rose, Michal, Vandenberghe, Peter, Verhoef, Gregor, Boogaerts, Marc, Wlodarska, Iwona, Kantarjian, Hagop, Marynen, Peter, Coutre, Steven E, Stone, Richard, Gilliland, D. Gary

Volltext

PB1849: TRIAL IN PROGRESS: PHASE IB/II STUDY OF SIREMADLIN IN COMBINATION WITH VENETOCLAX + AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSI... von Daver, N. G., Wei, A. H., Stein, E. M., DeAngelo, D. J., Pathak, D., Xu, Y., Grzesiak, S., Venditti, A.

Volltext

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes von Swords, R T, Watts, J, Erba, H P, Altman, J K, Maris, M, Anwer, F, Hua, Z, Stein, H, Faessel, H, Sedarati, F, Dezube, B J, Giles, F J, Medeiros, B C, DeAngelo, D J

Volltext

P1027: RESPONSES TO AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: HISTOPATHOLOGIC ANALYSES FROM EXPLORER AND PATHFINDER CLINICAL STUDIES von George, T., Karner, K. H., Moser, K. A., Rets, A., Reiter, A., Radia, D. H., Deininger, M., Lin, H.‐M., Dimitrijević, S., DeAngelo, D. J.

Volltext

P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC‐PHASE CHRONIC MYELOID LEUKEMIA (CP‐CML) FROM THE PACE AND OPTIC TRIALS von Apperley, J., Kantarjian, H., Deininger, M., Abruzzese, E., Cortes, J., Chuah, C., DeAngelo, D. J., DiPersio, J., Hochhaus, A., Lipton, J., Nicolini, F., Pinilla‐Ibarz, J., Rea, D., Rosti, G., Rousselot, P., Mauro, M., Shah, N., Talpaz, M., Vorog, A., Ren, X., Jabbour, E.

Volltext

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias von Cortes, J.E, Kim, D.-W, Pinilla-Ibarz, J, le Coutre, P, Paquette, R, Chuah, C, Nicolini, F.E, Apperley, J.F, Khoury, H.J, Talpaz, M, DiPersio, J, DeAngelo, D.J, Abruzzese, E, Rea, D, Baccarani, M, Müller, M.C, Gambacorti-Passerini, C, Wong, S, Lustgarten, S, Rivera, V.M, Clackson, T, Turner, C.D, Haluska, F.G, Guilhot, F, Deininger, M.W, Hochhaus, A, Hughes, T, Goldman, J.M, Shah, N.P, Kantarjian, H

Volltext